Last reviewed · How we verify
SMC021 Oral Calcitonin
SMC021 Oral Calcitonin works by mimicking the action of the naturally occurring hormone calcitonin to lower blood calcium levels.
SMC021 Oral Calcitonin works by mimicking the action of the naturally occurring hormone calcitonin to lower blood calcium levels. Used for Treatment of hypercalcemia of malignancy.
At a glance
| Generic name | SMC021 Oral Calcitonin |
|---|---|
| Sponsor | Nordic Bioscience A/S |
| Drug class | Calcitonin |
| Target | Calcitonin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Calcitonin is a hormone produced by the thyroid gland that helps regulate calcium levels in the blood. By administering calcitonin orally, SMC021 Oral Calcitonin aims to reduce blood calcium levels in patients with hypercalcemia or other conditions where calcium regulation is disrupted.
Approved indications
- Treatment of hypercalcemia of malignancy
Common side effects
- Nausea
- Injection site reaction
- Hypocalcemia
Key clinical trials
- Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (PHASE3)
- Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study) (PHASE3)
- A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D (PHASE3)
- Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide). (PHASE2)
- Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women (PHASE1)
- Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SMC021 Oral Calcitonin CI brief — competitive landscape report
- SMC021 Oral Calcitonin updates RSS · CI watch RSS
- Nordic Bioscience A/S portfolio CI